Department of Electrical and Biomedical Engineering, California State University Long Beach, CA, USA.
Cardiol J. 2011;18(3):326-31.
Current state-of-the art implantable cardioverter-defibrillator (ICD) systems have been proven to be safe and effective in treating ventricular arrhythmias leading to cardiac death. ICDs require placement of at least one lead in, or on, the heart. Surgical placement under fluoroscopy and the ongoing presence of the transvenous leads within the patient's heart are associated with a significant proportion of the complications related to this well-established and highly effective therapy. A new ICD has been developed that is implanted entirely subcutaneously (S-ICD), thus eliminating the need for lead placement in or on the heart and simplifying surgery by eliminating the need for imaging equipment. Recent clinical studies suggest that the S-ICD system provides a viable alternative to conventional transvenous devices that may reduce barriers to treatment and lead to the wider adoption of this life-saving therapy.
目前，已证实最先进的植入式心脏复律除颤器 (ICD) 系统在治疗导致心源性死亡的室性心律失常方面是安全且有效的。ICD 需要将至少一根导线置于心脏内或心脏上。在透视引导下进行手术放置和经静脉导线持续存在于患者心脏内，与这一成熟且高效的治疗方法相关的许多并发症都有关联。现已开发出一种完全经皮下植入的新型 ICD（S-ICD），因此无需在心脏内或心脏上放置导线，通过消除对影像设备的需求简化了手术。最近的临床研究表明，S-ICD 系统为传统经静脉器械提供了一种可行的替代方案，可能降低治疗障碍并推动这种救命疗法的更广泛应用。
